立川　正憲

東北大学院薬学研究科 薬物送達学分野　准教授

Message

これまで、異分野の一流の研究者との出会い、共に研究をさせていただいたことによって、ものの見方・価値観や研究の進め方に至るまで、さまざまな刺激を受けてきました。これらの接点で、いつも思いがけない発見やブレークスルーが生まれるというのは、身をもって実感しています。ファーマコキネティクス畑で学んできたものの強みを土台としながら、最先端技術と薬剤学の接点、ドラッグデリバリー、新技術の開発をキーワードに、10年20年先の健康福祉にどのように貢献できるかを考えながら、研究を進めていきたいと思います。
学生のみなさん、大学院を修了、学位を取得して、新たな環境に自分を置いた時に、また逆風に会った時に初めて、送達で学んだものの何かが大きな財産となって自分に残っていることに初めて気付くといいます。これは、卒業生の多くが認めることです。これから、薬物送達学分野の門下生が、国内だけでなく、世界に向けてさらに大きな力になって、社会に貢献できることを心から望んでおります。

Masanori Tachikawa, Ph.D.

Associate Professor
Division of Membrane Transport and Drug Targeting,
Graduate School of Pharmaceutical Sciences,
Tohoku University
6-3 Aramaki, Sendai, 980-8578, JAPAN
E-mail: tachi@mopera.net

Membership of Academic Societies

国際学会誌Editorial Advisory Board

国際学会誌Editorial Board


学会等世話人・学術委員等

Major accomplishments

Education

Research and professional experience

Awards

Major Research Interests

研究プロジェクト（研究代表者）

  1. 挑戦的萌芽研究 「血液脳関門輸送機能賦活化による認知症予防 」(2013-)
  2. 厚生労働科学研究 革新的がん医療実用化研究事業「標的タンパク質絶対定量情報を基盤とする悪性脳腫瘍の分子標的療法に関する臨床的特性の分子基盤解明」(2014-)
  3. 東北大学学際科学フロンティア研究所 学際研究支援プログラム「プラズマ膜輸送ダイナミクスの解明と医用応用」(2014-)
  1. 若手研究(A) 「血液脳関門ヘミチャネルの病態生理学的役割と分子標的診断・治療 」(2010-2013)
  2. 新エネルギー・産業技術総合開発機構(NEDO) 環境・医療分野の国際研究開発・実証プロジェクト／フランスにおける国際共同研究開発・実証事業「On-Demand Multi-mixed Protein Quantification Kitの研究開発」 (2012-2013)
  3. 科学技術振興機構 研究成果最適展開支援プログラム(A-STEP)フィージビリティスタディステージ探索タイプ「がん個別化治療を目指した標的受容体タンパク質内修飾の高速解析技術」(2011-2012)
  4. 若手研究(B)「脳関門輸送系による痙攣誘発性物質の中枢障害回避機構 」(2006-2007)

Publications

Original Articles

  1. Kaneko Y, Tachikawa M, Akaogi R, Fujimoto K, Ishibashi M, Uchida Y, Couraud PO, Ohtsuki S, Hosoya KI, Terasaki T (2015) Contribution of pannexin 1 and connexin 43 hemichannels to extracellular calcium-dependent transport dynamics in human blood-brain barrier endothelial cells. J Pharmacol Exp Ther 353:192-200.
  2. Sakamoto A, Matsumaru T, Yamamura N, Suzuki S, Uchida Y, Tachikawa M, Terasaki T (2015) Drug transporter protein quantification of immortalized human lung cell lines derived from tracheo-bronchial epithelial cells (Calu-3 and BEAS2-B), bronchiolar-alveolar cells (NCI-H292 and NCI-H441) and alveolar type II-like cells (A549) by liquid chromatography-tandem mass spectrometry. J Pharm Sci Epub ahead of print (doi: 10.1002/jps.24381).
  3. Kasai Y, Akanuma SI, Kubo Y, Tachikawa M, Hosoya K (2014) Pharmacokinetics of guanidinosuccinic acid in rat blood and cerebrospinal fluid. Drug Metab Pharmacokinet 29:97-100.
  4. Ito S, Ohtsuki S, Murata S, Katsukura Y, Suzuki H, Funaki M, Tachikawa M, Terasaki T (2014) Involvement of insulin-degrading enzyme in insulin- and atrial natriuretic peptide-sensitive internalization of amyloid-β peptide in mouse brain capillary endothelial cells. J Alzheimers Dis 38:185-200.
  5. Yahara T, Tachikawa M, Akanuma S, Kubo Y, Hosoya K (2014) Amino Acid Residues Involved in the Substrate Specificity of TauT/SLC6A6 for Taurine and γ-Aminobutyric Acid. Biol Pharm Bull 37:817-825.
  6. Akanuma S, Higuchi T, Higashi H, Ozeki G, Tachikawa M, Kubo Y, Hosoya K (2014) Transporter-mediated prostaglandin E2 elimination across the rat blood-brain barrier and its attenuation by the activation of N-methyl-D-aspartate receptors. Drug Metab Pharmacokinet 29:387-393.
  7. Eskilsson A, Tachikawa M, Hosoya K, Blomqvist A (2014) Distribution of microsomal prostaglandin E synthase-1 in the mouse brain. J Comp Neurol 522:3229-44.
  8. Gartzke D, Delzer J, Laplanche L, Uchida Y, Hoshi Y, Tachikawa M, Terasaki T, Sydor J, Fricker G (2014) Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases. Pharm Res Epub ahead of print.
  9. Ohtsuki S, Ikeda C, Uchida Y, Sakamoto Y, Miller F, Glacial F, Decleves X, Scherrmann JM, Couraud PO, Kubo Y, Tachikawa M, Terasaki T (2013) Quantitative Targeted Absolute Proteomic Analysis of Transporters, Receptors and Junction Proteins for Validation of Human Cerebral Microvascular Endothelial Cell Line hCMEC/D3 as a Human Blood-Brain Barrier Model. Mol Pharm 10:289-296.
  10. Kubo Y, Kusagawa Y, Tachikawa M, Akanuma SI, Hosoya K (2013) Involvement of a Novel Organic Cation Transporter in Verapamil Transport Across the Inner Blood-Retinal Barrier. Pharm Res 30:847-856.
  11. Akanuma S, Soutome T, Hisada E, Tachikawa M, Kubo Y, Hosoya K (2013) Na+-independent nucleoside transporters regulate adenosine and hypoxanthine levels in Müller cells and the inner blood-retinal barrier. Invest Ophthalmol Vis Sci 54:1469-1477.
  12. Yoneyama T, Ohtsuki S, Ono M, Ohmine K, Uchida Y, Yamada T, Tachikawa M, Terasaki T (2013) Quantitative Targeted Absolute Proteomics-Based Large-Scale Quantification of Proline-Hydroxylated α-Fibrinogen in Plasma for Pancreatic Cancer Diagnosis. J Proteome Res 12:753-762.
  13. Hoshi Y, Uchida Y, Tachikawa M, Inoue T, Ohtsuki S, Terasaki T (2013) Quantitative atlas of blood-brain barrier transporters, receptors and tight junction proteins in rats and common marmoset. J Pharm Sci 102:3343-55.
  14. Akanuma S, Hirose S, Tachikawa M, Hosoya K (2013) Localization of organic anion transporting polypeptide (Oatp) 1a4 and Oatp1c1 at the rat blood-retinal barrier. Fluids Barriers CNS. 10:29.
  15. Uchida Y, Tachikawa M, Obuchi W, Hoshi Y, Tomioka Y, Ohtsuki S, Terasaki T (2013) A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood-brain barrier in ddY, FVB, and C57BL/6J mice. Fluids Barriers CNS 10:21.
  16. Sakamoto A, Matsumaru T, Yamamura N, Uchida Y, Tachikawa M, Ohtsuki S, Terasaki T (2013) Quantitative expression of human drug transporter proteins in lung tissues: analysis of regional, gender, and interindividual differences by liquid chromatography-tandem mass spectrometry. J Pharm Sci 102:3395-406.
  17. Tachikawa M, Ikeda S, Fujinawa J, Hirose S, Akanuma S, Hosoya K (2012) g-Aminobutyric acid transporter 2 mediates the hepatic uptake of guanidinoacetate, the creatine biosynthetic precursor, in rats. PLoS One. 7:e32557.
  18. Ando D, Kubo Y, Akanuma S, Yoneyama D, Tachikawa M, Hosoya K (2012) Function and regulation of taurine transport in Müller cells under osmotic stress. Neurochem Int 60:597-604.
  19. Kubo Y, Fukui E, Akanuma S, Tachikawa M, Hosoya K (2012) Application of membrane permeability evaluated in in vitro analyses to estimate blood-retinal barrier permeability. J Pharm Sci 101:2596-2605.
  20. Ikeda S, Tachikawa M, Akanuma S, Fujinawa J, Hosoya K (2012) Involvement of g-aminobutyric acid transporter 2 in the hepatic uptake of taurine in rats. Am J Physiol Gastrointest Liver Physiol 303:G291-297.
  21. Tachikawa M, Tsuji K, Yokoyama R, Higuchi T, Ozeki G, Yashiki A, Akanuma S, Hayashi K, Nishiura A, Hosoya K (2012) A clearance system for prostaglandin D2, a sleep-promoting factor, in the cerebrospinal fluid: role of the blood-cerebrospinal barrier transporters. J Pharmacol Exp Ther 343:608-16.
  22. Tachikawa M, Ozeki G, Higuchi T, Akanuma S, Tsuji K, Hosoya K (2012) Role of the blood-cerebrospinal fluid barrier transporter as a cerebral clearance system for prostaglandin E2 produced in the brain. J Neurochem 12:750-760.
  23. Tachikawa M, Okamoto M, Hirose S, Yoneyama D, Akanuma S, Terasaki T, Hosoya K (2011) The Inner Blood-Retinal Barrier Mediates L-Isomer-Predominant Transport of Serine. J Pharm Sci100:3892-903.
  24. Fujiyoshi M, Tachikawa M, Ohtsuki S, Ito S, Uchida Y, Akanuma S, Kamiie J, Hashimoto T, Hosoya K, Iwatsubo T, Terasaki T (2011) Amyloid-b peptide(1-40) elimination from cerebrospinal fluid involves low-density lipoprotein receptor-related protein 1 at the blood-cerebrospinal fluid barrier. J Neurochem 118:407-415.
  25. Kasai Y, Tachikawa M, Hirose S, Akanuma S, Hosoya K (2011) Transport systems of serine at the brain barriers and in brain parenchymal cells. J Neurochem118:304-13.
  26. Yahara T, Tachikawa M, Akanuma S, Hosoya K (2011) Hypertonicity Enhances GABA Uptake by Cultured Rat Retinal Capillary Endothelial Cells. Drug Metab Pharmacokinet 25:611-615.
  27. Ha Y, Saul A, Tawfik A, Williams C, Bollinge K, Smith R, Tachikawa M, Zorrilla E, Ganapathy V, Smith S (2011) Late-onset inner retinal dysfunction in mice lacking sigma receptor 1 (sR1). Invest Ophthalmol Vis Sci 52:7749-7760.
  28. Akanuma S, Uchida Y, Ohtsuki S, Tachikawa M, Terasaki T, Hosoya K (2011) Attenuation of prostaglandin E2 elimination across the mouse blood-brain barrier in lipopolysaccharide-induced inflammation and additive inhibitory effect of cefmetazole. Fluids Barriers CNS 8:24.
  29. Tachikawa M, Murakami K, Martin P, Hosoya K, Ganapathy V (2011) Retinal transfer of nicotinate by H+-monocarboxylate transporter at the inner blood-retinal barrier. Microvas Res82:385-390.
  30. Akanuma S, Uchida Y, Ohtsuki S, Kamiie J, Tachikawa M, Terasaki T, Hosoya K (2011) Molecular-weight-dependent, anionic-substrate-preferential transport of b-lactam antibiotics via multidrug resistance-associated protein 4. Drug Metab Pharmacokinet 26:602-611.
  31. Matsuyama R, Tomi M, Akanuma SI, Tabuchi A, Kubo Y, Tachikawa M, Hosoya K (2011) Up-regulation of L-Type Amino Acid Transporter 1 (LAT1) in Cultured Rat Retinal Capillary Endothelial Cells in Response to Glucose Deprivation. Drug Metab Pharmacokinet 27:317-324.
  32. Tachikawa M, Takeda Y, Tomi M, Hosoya K (2010) Involvement of OCTN2 in the transport of acetyl-L-carnitine across the inner blood-retinal barrier. Invest Ophthalmol Vis Sci 51:430-436.
  33. Akanuma S, Hosoya K, Ito S, Tachikawa M, Terasaki T, Ohtsuki S (2010) Involvement of multidrug associated-protein 4 in efflux transport of prostaglandin E2 across mouse blood-brain barrier and its inhibition by intravenous administration of cephalosporins. J Pharmacol Exp Ther 333:912-919.
  34. Ohkura Y, Akanuma S, Tachikawa M, Hosoya K (2010) Blood-to-retina transport of biotin via Na+-dependent multivitamin transporter (SMVT) at the inner blood-retinal barrier. Exp Eye Res 91:387-392.
  35. Hosoya K, Yamamoto A, Akanuma S, Tachikawa M (2010) Lipophilicity and transporter influence on blood-retinal barrier permeability: a comparison with blood-brain barrier permeability. Pharm Res 27:2715-2724.
  36. Hosoya K, Ichikawa T, Akanuma S, Hirose S, Tachikawa M (2010) Glycine and L-arginine transport in cultured Müller glial cells (TR-MUL). Neurochem Int 57:262-268.
  37. Yoneyama D, Shinozaki Y, Lu WL, Tomi M, Tachikawa M, Hosoya K (2010) Involvement of system A in the retina-to-blood transport of l-proline across the inner blood-retinal barrier. Exp Eye Res 90:507-513.
  38. Yamamoto A, Akanuma S, Tachikawa M, Hosoya K (2010) Involvement of LAT1 and LAT2 in the high- and low-affinity transport of L-leucine in human retinal pigment epithelial cells (ARPE-19 cells). J Pharm Sci 99:2475-2482
  39. Tachikawa M, Kasai Y, Yokoyama R, Fujinawa J, Ganapathy V, Terasaki T, Hosoya K (2009) The blood-brain barrier transport and cerebral distribution of guanidinoacetate in rats: involvement of creatine and taurine transporters. J Neurochem 111:499-509.
  40. Tachikawa M, Tsuji K, Ikeda S, Hosoya K (2009) Lysophospholipids enhance taurine release from rat retinal vascular endothelial cells under hypoosmotic stress. Microvas Res 78:332-337.
  41. Tomi M, Kitade N, Hirose S, Yokota N, Akanuma S, Tachikawa M, Hosoya K (2009) Cationic amino acid transporter 1 (CAT1)-mediated L-arginine transport at the inner blood-retinal barrier. J Neurochem 111:716-725.
  42. Okamoto M, Akanuma S, Tachikawa M, Hosoya K (2009) Characteristics of glycine transport across the inner blood-retinal barrier. Neurochem Int 55:789-795
  43. Akanuma S, Yamamoto A, Okayasu S, Tachikawa M, Hosoya K (2009) High-Density Lipoprotein-Associated alpha-Tocopherol Uptake by Human Retinal Pigment Epithelial Cells (ARPE-19 Cells): the Irrelevance of Scavenger Receptor Class B, Type I. Biol Pharm Bull 32:1131-1134.
  44. Hosoya K, Makihara A, Tsujikawa Y, Yoneyama D, Mori S, Terasaki T, Akanuma S, Tomi M, Tachikawa M (2009) Roles of inner blood-retinal barrier organic anion transporter 3 in the vitreous/retina-to-blood efflux transport of p-aminohippuric acid, benzylpenicillin, and 6-mercaptopurine. J Pharmacol Exp Ther 329:87-93.
  45. Tachikawa M, Fujinawa J, Takahashi M, Kasai Y, Fukaya M, Sakai K, Yamazaki M, Tomi M, Watanabe M, Sakimura K, Terasaki T, Hosoya K (2008) Expression and possible role of creatine transporter in the brain and at the blood-cerebrospinal fluid barrier as a transporting protein of guanidinoacetate, an endogenous convulsant. J Neurochem 107:768-778.
  46. Tachikawa M, Kasai Y, Takahashi M, Fujinawa J, Kitaichi K, Terasaki T, Hosoya K (2008) The blood-cerebrospinal fluid barrier is a major pathway of cerebral creatinine clearance: involvement of transporter-mediated process. J Neurochem 107:432-442.
  47. Tachikawa M, Toki H, Tomi M, Hosoya K (2008) Gene expression profiles of ATP-binding cassette transporter A and C subfamilies in mouse retinal vascular endothelial cells. Microvasc Res 75:68-72.
  48. Yamada K, Hashimoto T, Yabuki C, Nagae Y, Tachikawa M, Strickland DK, Liu Q, Bu G, Basak JM, Holtzman DM, Ohtsuki S, Terasaki T, Iwatsubo T (2008) The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an in vitro model of the blood-brain barrier cells. J Biol Chem 283:34554-34562.
  49. Akanuma S, Ohtsuki S, Doi Y, Tachikawa M, Ito S, Hori S, Asashima T, Hashimoto T, Yamada K, Ueda K, Iwatsubo T, Terasaki T (2008) ATP-binding cassette transporter A1 (ABCA1) deficiency does not attenuate the brain-to-blood efflux transport of human amyloid-beta peptide (1-40) at the blood-brain barrier. Neurochem Int 52:956-961.
  50. Tomi M, Tajima A, Tachikawa M, Hosoya K (2008) Function of taurine transporter (Slc6a6/TauT) as a GABA transporting protein and its relevance to GABA transport in rat retinal capillary endothelial cells. Biochim Biophys Acta 1778:2138-2142.
  51. Hosoya K, Fujita K, Tachikawa M (2008) Involvement of reduced folate carrier 1 in the inner blood-retinal barrier transport of methyltetrahydrofolate. Drug Metab Pharmacokinet 23:285-292.
  52. Hosoya K, Kyoko H, Toyooka N, Kato A, Orihashi M, Tomi M, Tachikawa M (2008) Evaluation of amino acid-mustard transport as L-type amino acid transporter 1 (LAT1)-mediated alkylating agents. Biol Pharm Bull 31:2126-2130.
  53. Hosoya K, Nakamura G, Akanuma S, Tomi M, Tachikawa M (2008) Dehydroascorbic acid uptake and intracellular ascorbic acid accumulation in cultured Muller glial cells (TR-MUL). Neurochem Int 52:1351-1357.
  54. Tachikawa M, Okayasu S, Hosoya K (2007) Functional involvement of scavenger receptor class B, type I, in the uptake of alpha-tocopherol using cultured rat retinal capillary endothelial cells. Mol Vis 13:2041-2047.
  55. Tomi M, Arai K, Tachikawa M, Hosoya K (2007) Na+-independent choline transport in rat retinal capillary endothelial cells. Neurochem Res 32:1833-1842.
  56. Fujiyoshi M, Ohtsuki S, Hori S, Tachikawa M, Terasaki T (2007) 24S-hydroxycholesterol induces cholesterol release from choroid plexus epithelial cells in an apical- and apoE isoform-dependent manner concomitantly with the induction of ABCA1 and ABCG1 expression. J Neurochem 100:968-978.
  57. Nagase K, Tomi M, Tachikawa M, Hosoya K (2006) Functional and molecular characterization of adenosine transport at the rat inner blood-retinal barrier. Biochim Biophys Acta 1758:13-19.
  58. Asashima T, Hori S, Ohtsuki S, Tachikawa M, Watanabe M, Mukai C, Kitagaki S, Miyakoshi N, Terasaki T (2006) ATP-binding cassette transporter G2 mediates the efflux of phototoxins on the luminal membrane of retinal capillary endothelial cells. Pharm Res 23:1235-1242.
  59. Bhongsatiern J, Ohtsuki S, Tachikawa M, Hori S, Terasaki T (2005) Retinal-specific ATP-binding cassette transporter (ABCR/ABCA4) is expressed at the choroid plexus in rat brain. J Neurochem 92:1277-1280.
  60. Tachikawa M, Watanabe M, Hori S, Fukaya M, Ohtsuki S, Asashima T, Terasaki T (2005) Distinct spatio-temporal expression of ABCA and ABCG transporters in the developing and adult mouse brain. J Neurochem 95:294-304.
  61. Tomi M, Mori M, Tachikawa M, Katayama K, Terasaki T, Hosoya K (2005) L-type amino acid transporter 1-mediated L-leucine transport at the inner blood-retinal barrier. Invest Ophthalmol Vis Sci 46:2522-2530.
  62. Nakashima T, Tomi M, Tachikawa M, Watanabe M, Terasaki T, Hosoya K (2005) Evidence for creatine biosynthesis in Muller glia. Glia 52:47-52.
  63. Nakashima T, Tomi M, Katayama K, Tachikawa M, Watanabe M, Terasaki T, Hosoya K (2004) Blood-to-retina transport of creatine via creatine transporter (CRT) at the rat inner blood-retinal barrier. J Neurochem 89:1454-1461.
  64. Shiiki T, Ohtsuki S, Kurihara A, Naganuma H, Nishimura K, Tachikawa M, Hosoya K, Terasaki T (2004) Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci 24:9632-9637.
  65. Hori S, Ohtsuki S, Tachikawa M, Kimura N, Kondo T, Watanabe M, Nakashima E, Terasaki T (2004) Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). J Neurochem 90:526-536.
  66. Tachikawa M, Fukaya M, Terasaki T, Ohtsuki S, Watanabe M (2004) Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuron-glial relationship for brain energy homeostasis. Eur J Neurosci 20:144-160.
  67. Deguchi Y, Okutsu H, Okura T, Yamada S, Kimura R, Yuge T, Furukawa A, Morimoto K, Tachikawa M, Ohtsuki S, Hosoya K, Terasaki T (2002) Internalization of basic fibroblast growth factor at the mouse blood-brain barrier involves perlecan, a heparan sulfate proteoglycan. J Neurochem 83:381-389.
  68. Ohtsuki S, Tachikawa M, Takanaga H, Shimizu H, Watanabe M, Hosoya K, Terasaki T (2002) The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain. J Cereb Blood Flow Metab 22:1327-1335.

Reviews

  1. Tachikawa M, Hosoya K, Terasaki T (2014) Pharmacological significance of prostaglandin E2 and D2 transport at the brain barriers. Adv Pharmacol 71:337-60.
  2. Ohtsuki S, Hirayama M, Ito S, Uchida Y, Tachikawa M, Terasaki T (2014) Quantitative targeted proteomics for understanding the blood-brain barrier: towards pharmacoproteomics. Expert Rev Proteomics 11:303-313.
  3. Tachikawa M, Hosoya K (2011) Transport characteristics of guanidino compounds at the blood-brain barrier and blood-cerebrospinal fluid barrier: relevance to neural disorders. Fluids Barriers CNS 8:13.
  4. Hosoya K, Tachikawa M (2011) Roles of organic anion/cation transporters at the blood-brain and blood-cerebrospinal fluid barriers involving uremic toxins. Clin Exp Nephrol 15:478–485.
  5. Hosoya K, Tomi M, Tachikawa M (2011) Strategies for therapy of retinal diseases using systemic drug delivery: relevance of transporters at the blood-retinal barrier. Expert Opin Drug Deliv 8:1571-1587.
  6. Hosoya K, Tachikawa M (2009) Inner blood-retinal barrier transporters: Role of retinal drug delivery. Pharm Res 26:2055-2065.

Book chapters/著書

  1. Tachikawa M, Uchida Y, Ohtsuki S, Terasaki T (2014) Recent progress in the blood-brain barrier and the blood-CSF barrier transport research: Pharmaceutical relevance of drug delivery to the brain. Drug Delivery to the Brain – Physiological Concepts, Methodologies and Approaches, Hammarlund-Udenaes M, de Lange E, and Thorne R (Ed), Springer, New York, pp23-62.
  2. Uchida Y, Tachikawa M, Ohtsuki S, Terasaki T (2014) Blood-brain barrier (BBB) pharmacoproteomics: a new research field opened up by quantitative targeted absolute proteomics (QTAP). Drug Delivery to the Brain – Physiological Concepts, Methodologies and Approaches, Hammarlund-Udenaes M, de Lange E, and Thorne R (Ed), Springer, New York, pp63-100.
  3. Hosoya K, Tachikawa M (2012) The inner blood-retinal barrier: molecular structure and transport biology. Biology and Regulation of Blood-Tissue Barriers, Cheng C. Y. (Ed), Landes Bioscience-Springer, New York, pp85-104.
  4. Tachikawa M, Hosoya K, Smith SB, Martin PM, Ganapathy V (2012) Transport of drugs across the inner and outer blood-retinal barriers: Relevance of transporters in the retinal blood vessel endothelium and the retinal pigment epithelium. Advances in Ocular Drug Delivery, Mitra A. K. (Ed), Research Signpost, Kerala, pp 1-31.
  5. Tachikawa M, Hosoya K, Ohtsuki S, Terasaki T (2007) A novel relationship between creatine transport at the blood-brain and blood-retinal barriers, creatine biosynthesis, and its use for brain and retinal energy homeostasis. Subcell Biochem 46:83-98.
  6. Tachikawa M, Ganapathy V, Hosoya K (2011) Systemic route for retinal drug delivery: role of the blood-retinal barrier transporters. Drug Product Development for the Back of the Eye, Kompella U. B. and Edelhauser H. F. (Ed), American Association of Pharmaceutical Scientists, Press-Springer, New York, pp 85-109.

Review articles (Japanese)

  1. 立川正憲、内田康雄、寺崎哲也 (2015) 血液脳関門, 脳科学辞典, doi：10.14931/bsd.3373
  2. 立川正憲、内田康雄、寺崎哲也 (2013) 動的インターフェースとしての脳関門輸送システムと脳関門生理学・創薬研究, BRAIN and NERVE, 65:121-137.
  3. 立川正憲，赤沼伸乙，寺崎哲也 (2013) 脳関門プロスタグランジン輸送の分子病態生理, 細胞工学, 31:946-949.
  4. 内田康雄，立川正憲，寺崎哲也 (2013) 定量的標的絶対プロテオミクス（QTAP）に基づくin vitro実験系からの血液脳関門輸送機能の再構築, 細胞工学, 31:955-961.
  5. 内田康雄、立川正憲、星裕太朗、寺崎哲也 (2013) 血液脳関門トランスポートソームの定量的絶対発現プロファイル：動物種間，系統間，野生型-遺伝子欠損マウス間の相違性と類似性, 脳21, 16:46-52.
  6. 立川正憲、内田康雄、寺崎哲也 (2013) 標的絶対定量プロテオミクスが拓くヒト血液脳関門輸送機能研究, Drug Delivery System, 28:270-278.
  7. 内田康雄、佐藤和貴、黒田広樹、星裕太朗、立川正憲、寺崎哲也 (2013) 血液脳関門における定量的標的絶対プロテオミクス解析, 血管医学, 14:399-409.
  8. 内田康雄、立川正憲、寺崎哲也 (2012) 定量的絶対標的プロテオミクスに基づくトランスポーター研究の新展開, 細胞工学, 31:587-588.
  9. 立川正憲、内田康雄、大槻純男、寺崎哲也 (2011) 定量的絶対標的プロテオミクスに基づくヒト血液脳関門におけるトランスポーターの発現と生理機能, 脳21, 14:42-48.
  10. 立川正憲, 寺崎哲也, 渡辺雅彦 (2005) クレアチンを介した脳内エネルギー代謝の調節機構とニューロン・グリア相関, Clinical Neuroscience 23: 158-160.
  11. 立川正憲, 寺崎哲也 (2005) 脳内エネルギー代謝における血液脳関門トランスポーターの生理的役割, 化学と生物, 43:166-171.
  12. 大槻純男, 立川正憲, 堀里子, 寺崎哲也 (2003) 脳を守る脳関門トランスポーター、未来材料, 3: 2-6.

Book Chapters (Japanese)

  1. 内田康雄、立川正憲 (2014) ファーマコプロテオミクス, 薬剤学実験法必携マニュアルII生物薬剤学 日本薬剤学会出版委員会編, pp312-324.
  2. 寺崎哲也、立川正憲 (2012) 分布(第6章), エピソード薬物動態学, 辻彰、寺崎哲也、荻原琢男編, pp169-192.

国際会議等招待講演 Invited lectures

  1. Tachikawa M., Plasticity and robustness of the blood-brain-barrier transporters, channels, and receptors: a study of  advanced quantitative targeted proteomics, Symposium 7: New Strategies in the Human CNS Barriers Research: The Development of New CNS Drugs and Therapies for the CNS Disorders, 19th North American ISSX/29th JSSX Meeting, October 21, 2014, San Francisco, USA
  2. Tachikawa M., Channels at the Barriers: A Non-Transporter-Mediated Gateway, Gordon Research Conference, Barriers of the CNS, June 19, 2014, Colby-Sawyer College, New London, USA
  3. Tachikawa M., Pharmacological impact of the brain barrier prostaglandin transport. 20th Annual Blood-Brain Barrier (BBB) meeting, March 20–22, 2014, Sunriver Resort, Oregon, USA
  4. Tachikawa M., Proteomics-based technology as a new path to toxicological evaluation. 2012 International Symposium on Green Toxicology & Technology: Prediction of Kidney Toxicity, Seoul, South Korea, September 7, 2012
  5. Tachikawa M An in vivo method to study transfer of drugs across inner and outer blood-retinal barrier. Medical college of Georgia, Vision Discovery Institute, Vision DIGM Seminar, Augusta　(USA), March 8, 2010

国内学会/シンポジウム等講演

  1. 立川正憲、寺崎哲也：On-Demand Multi-mixed Protein Quantification Kitの研究開発、BioJapan 2014 NEDOセミナー「NEDO成果発表及び新規事業紹介〜これまでと明日へ〜」、2014年10月16日、横浜
  2. 立川正憲：標的絶対定量プロテオミクス(QTAP)を活用した細胞膜輸送ダイナミクスの解明、学際科学フロンティア研究所ＦＲＩS 第７２回インフォーマル・セミナー、2014年8月26日、仙台
  3. 立川正憲、星裕太朗、佐藤和貴、内田康雄、大槻純男、寺崎哲也：標的定量プロテオミクス解析に基づく病態時?液脳関?輸送系の可塑的変化の解明、ワークショップ5 DDSを指向したトランスポーター研究、第30回日本DDS学会学術集会、2014年7月31日、東京
  4. 立川正憲：生体膜薬物輸送研究におけるタンパク質絶対定量情報の活用、シンポジウム11 個別化医療におけるトランスポーター情報の活用、第22回クリニカルファーマシーシンポジウム 医療薬学フォーラム2014、2014年6月29日、東京
  5. 立川正憲：タンパク質をはかる技術の創薬・個別化医療への貢献、多機能性人工エキソソーム（iTEX)医薬品化実践を通じた操薬人育成事業特別講演会、2014年 5月27日、徳島
  6. 立川正憲、金子洋介、赤荻諒、内田康雄、大槻純男、寺崎哲也：血液脳関門ヘミチャネルの病態生理学的役割と中枢疾患治療標的としての可能性、日本薬学会第134年会、2014年3月27-30日、熊本
  7. 立川正憲：IVIVE of Transporters - Part I & II (Transporter introduction, In Vitro assays and data analysis) 第3回Simcyp東京ワークショップ、2012年11月16日、東京
  8. 立川正憲：トランスポーターと応用健康科学、立命館大学スポーツ健康科学部 スポーツ健康科学セミナーＩ、2012年5月23日、草津
  9. 立川正憲：グアニジノ化合物群の体内動態と疾患、神奈川県立こども医療センターセミナー、2012年4月18日、横浜
  10. 立川正憲：グアニジノ化合物のトランスポーターと脳関門輸送、第32回グア ニジノ化合物研究会 、2011年10月29日、酒田
  11. 立川正憲　神経-グリア回路網における脳関門トランスポーターの位置付け. 九州大学農学研究院システム生物学セミナー、2011年8月25日、福岡
  12. 立川正憲, 細谷健一　「脳関門-神経-グリア」機能的ネットワークにおけるトランスポーターの役割. 第32回生体膜と薬物の相互作用シンポジウム、2010年11月30日、富山
  13. 立川正憲 「脳内エネルギー貯蔵システムと脳関門-グリア-ニューロンの機能的連携」九州大学バイオアーキテクチャーセンターセミナー、2007年5月30日、福岡
  14. 立川正憲 「脳関門クレアチントランスポーター (SLC6A8)の病態生理学的役割」 第264回東北大学薬学研究科セミナー/文部科学省21世紀COEプログラム拠点形成事業「シグナル伝達病の治療戦略創生拠点」共催、2007年11月28日、仙台
  15. 立川正憲 「脳・網膜関門の新たな生理機能の探索」 第202回東北大学薬学研究科セミナー/文部科学省21世紀COEプログラム拠点形成事業「シグナル伝達病の治療戦略創生拠点」共催、2006年6月24日、仙台